

November 21, 2011

Ajinomoto Pharmaceuticals Co., Ltd.

Interprotein Corporation

Ajinomoto Pharmaceuticals Co., Ltd. and Interprotein Corporation Sign a Joint R&D and Commercialization Agreement

Ajinomoto Pharmaceuticals Co., Ltd. (President, Tomoyasu Toyoda; Headquarters, Chuo-ku, Tokyo; hereinafter “Ajinomoto Pharmaceuticals”) and Interprotein Corporation (President, Masato Hosoda; Headquarters, Osaka City, Osaka; hereinafter “Interprotein”) announced today that the two companies have signed a joint R&D and commercialization agreement for small molecular PPI inhibitors*¹ targeting an endogenous ligand.

Both companies will collaborate to develop unique novel pharmaceuticals utilizing the expertise of Interprotein in molecular designing technology and R&D know-how of Ajinomoto Pharmaceuticals together.

Under this agreement, Interprotein gives Ajinomoto Pharmaceuticals a worldwide exclusive license to develop, manufacture and sell the inhibitors, and Ajinomoto Pharmaceuticals pays to Interprotein an initial payment, milestones and royalties.

(*1)

PPI (Protein-Protein Interaction) inhibitors: Small molecular weight compounds that inhibit interactions between proteins.

Contact	
Ajinomoto Pharmaceuticals Co., Ltd. Corporate Planning Dept. TEL: +81-(0)3-6280-9802 FAX: +81-(0)3-6280-9912	Interprotein Corporation Contact person: Komatsu, Business Development Dept. TEL/FAX: +81-(0)42-770-9477 e-mail: info@interprotein.com